Retinal vein occlusion

Retinal vein occlusion happens when a clot blocks a vein in the eye, leading to vision loss. Current treatments manage the fluid buildup but do not remove the clot. This trial tests whether a robot can safely guide a tiny needle into the blocked vein to inject tPA, a clot-dissolv…

This study looks at whether adding targeted laser treatment to the standard ranibizumab injections can help people with macular edema (swelling) from a central retinal vein occlusion need fewer injections over time. About 88 adults with this condition will receive either injectio…

This study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…

This early-stage trial is testing whether it is safe to inject a person's own bone marrow stem cells into their eye to treat vision loss from conditions like macular degeneration and diabetic retinopathy. Fifteen adults with severe vision loss will receive the injection and be mo…

This study tests a new, less invasive drainage procedure for people with advanced neovascular glaucoma whose eye pressure remains high despite treatment. The goal is to safely lower eye pressure and reduce the need for pressure-lowering drugs. The study involves 30 participants a…

This study compares a new numbing gel (chloroprocaine HCl 3%) to standard eye drops plus a shot for pain relief during eye injections. About 236 adults with conditions like diabetic macular edema or age-related macular degeneration will take part. The goal is to see if the gel wo…

This study is collecting long-term, real-world data from about 6,000 adults being treated with Roche eye medications (Faricimab or the Port Delivery System with Ranibizumab) for conditions like wet age-related macular degeneration and diabetic macular edema. The goal is to unders…

This study follows 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will collect data from routine clinic visits over one year to see how well the drug works and ho…